The BTN2A1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BTN2A1 gene in the human hepatic adenocarcinoma SK-HEP-1 cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of cells with targeted ablation of BTN2A1 expression. The polyclonal format mitigates clonal artifacts and provides a realistic representation of gene function across a genetically diverse cell population. This product is particularly suited for investigating BTN2A1-mediated immunomodulatory lipid antigen presentation without the constraints of single-cell clonal selection. It serves as an essential tool for dissecting the role of BTN2A1 in gamma delta T cell biology and tumor immunology.
The SK-HEP-1 cell line was originally established from the ascitic fluid of a patient with liver adenocarcinoma and exhibits a malignant hepatic epithelial phenotype. These cells are widely employed in hepatocellular carcinoma research due to their robust in vitro growth and retention of oncogenic signaling programs. As an adherent epithelial line, SK-HEP-1 facilitates genetic manipulation and subsequent functional assays, making it an ideal host for studying tumor cell-intrinsic pathways. Its origin from ascites also underscores its relevance to metastatic dissemination and the peritoneal tumor microenvironment.
BTN2A1 encodes a butyrophilin family member that acts as an intracellular sensor and presenter of phosphoantigens to the V??9V??2 T cell receptor. It cooperates with BTN3A1 to bind phosphorylated metabolites, including HMB-PP and IPP, produced by the mevalonate pathway and certain microbes. Upon phosphoantigen binding, BTN2A1 engages V??9V??2 TCR, initiating a signaling cascade involving protein kinase C theta (PKC??) and nuclear factor kappa-B (NF-??B). This pathway drives transcriptional upregulation of effector cytokines, notably IFN-?? and TNF-??, and primes ?æ? T cells for perforin/granzyme-mediated cytotoxicity. Upstream, BTN2A1 expression is upregulated by T cell receptor engagement and inflammatory cytokines such as IFN-??, establishing an amplification loop that reinforces ?æ? T cell activation. Consequently, BTN2A1 functions as a critical nexus connecting lipid metabolism to innate-like T cell immunity.
In the context of the SK-HEP-1 hepatic adenocarcinoma model, BTN2A1 disruption provides a powerful tool to dissect tumor-intrinsic mechanisms of immune evasion and ?æ? T cell recognition. Liver cancer cells often upregulate mevalonate pathway activity, leading to increased phosphoantigen production, which can be sensed by V??9V??2 T cells. By knocking out BTN2A1, researchers can specifically interrogate how loss of this antigen-presenting molecule alters T cell activation, cytokine secretion, and tumor cell killing. This model also enables investigation of potential crosstalk between BTN2A1 and other immune checkpoint regulators, as butyrophilins have been implicated in modulating T cell responses in cancer. Furthermore, the SK-HEP-1 background allows studies of lipid antigen presentation within the hepatic tumor microenvironment, offering insights into liver cancer immunotherapy strategies.
Typical applications of the BTN2A1 Knockout SK-HEP-1 Polyclonal Cells encompass a range of functional assays central to gamma delta T cell and cancer immunology research. Co-culture experiments with V??9V??2 T cells, combined with flow cytometric analysis of activation markers and intracellular cytokine staining, permit quantitative assessment of BTN2A1-dependent T cell stimulation. ELISA-based measurement of secreted IFN-?? and TNF-??, along with real-time cytotoxicity assays, provide functional readouts of effector responses. Western blotting and RT-qPCR can be employed to verify BTN2A1 disruption and monitor downstream signaling events involving PKC?? and NF-??B. These knockout cells are thus well-suited for studies of lipid antigen presentation. They also support research into autoimmune disease mechanisms and the development of immunotherapeutic interventions targeting the BTN2A1-BTN3A1-phosphoantigen axis. For additional product information and technical support, please contact Ascent Research.
